Hims & Hers Health (NYSE: HIMS) Stock Plunges 14% Following Major FTC Lawsuit Over Privacy & Billing; Hagens Berman Investigates Corporate Compliance and Investor Ramifications

Hims & Hers (HIMS) shares dropped 14.73% to $25.00 on July 29 after the FTC (with Utah and Los Angeles) sued the company over alleged improper practices. The complaint alleges deceptive sharing of sensitive health data with ad platforms (e.g., Meta and Snap) via tracking pixels/list matching and alleged ROSCA violations through subscription billing without informed consent and cancellation “dark patterns.” A shareholder rights firm is now investigating potential internal-control and financial-disclosure implications related to the alleged compliance and tracking/billing practices, extending near-term overhang risk for the stock.

Analysis

The market is likely still underpricing the difference between a one-time legal headline and a forced change to HIMS’ growth engine. If consent mechanics and cancellation friction were supporting conversion, then the real damage is not damages claims but a permanent reset in CAC payback and subscriber retention; that tends to hit valuation over several quarters, not just on the first shock. In this setup, the key risk is that compliance remediation slows top-line growth while legal spend rises, compressing both operating margin and the multiple investors are willing to pay for growth.

The second-order spillover is to the digital-ad ecosystem and privacy-sensitive advertisers. META and SNAP are not primary losers financially from this case, but any ruling or settlement narrative that amplifies scrutiny around pixels, customer list matching, and health-data use can raise compliance costs across ad-tech and make attribution less reliable for direct-to-consumer health names. That is modest for platform revenue in the near term, but it is meaningful for smaller consumer-health advertisers that rely on precise targeting to make unit economics work.

Contrarian view: the immediate drawdown may already reflect the headline risk, but the consensus may be missing that a litigation overhang can be self-reinforcing if it impairs app-store ratings, consumer trust, and paid acquisition efficiency. The thesis would be falsified if HIMS quickly proves clean consent flows, shows no cohort deterioration in upcoming quarters, and absorbs remediation without a guide-down; absent that, this looks more like a months-long multiple compression story than a one-day event.

Key Decisions for Investors

• Short HIMS on any relief rally above the post-event range; prefer a 1-3 month put spread over outright puts to limit premium decay, targeting additional downside if management guidance implies higher CAC or lower retention.
• Pair trade: long TDOC / short HIMS for 1-3 months if the market starts rewarding cleaner telehealth monetization models; thesis is that compliance-heavy remediation hurts HIMS’ growth multiple more than it helps peers.
• Buy META and SNAP only as a tactical hedge, not a core long; treat them as low-conviction overhang names and exit if no regulator follow-through emerges within 30-45 days.
• Set an alert on HIMS next earnings for cohort retention, cancellation rates, and CAC disclosure; if any of those deteriorate, add to the short because the catalyst path shifts from legal to fundamental.
• Avoid chasing a bottom-fish long in HIMS until there is evidence of settlement clarity or a revised compliance framework; the risk/reward is poor if the business model needs meaningful redesign.